Knigge U, Thuesen B, Dejgaard A, Bennett P, Christiansen P M
Department of Surgical Gastroenterology, Hvidovre Hospital, University of Copenhagen, Denmark.
Eur J Clin Pharmacol. 1989;37(3):305-7. doi: 10.1007/BF00679790.
The effects of treatment for 2 years with the histamine H2-receptor antagonist ranitidine (100 or 200 mg b.d. for 6 weeks followed by 100 or 200 mg daily) on plasma concentrations of pituitary and peripheral hormones in ten men with duodenal ulcer have been investigated. Stimulation tests with TRH 200 micrograms i.v. and LHRH 100 micrograms i.v. were performed before, during (6 and 24 months), and at least 6 months after treatment. Basal and TRH-stimulated prolactin (PRL) secretion was marginally reduced after treatment for 6 months, but not for 24 months. The LH response to LHRH was slightly increased after treatment for 6 months and 24 months and after the end of treatment. The plasma concentrations of TSH, FSH, cortisol, androgenic hormones, and thyroid hormones did not change significantly during treatment. No adverse effects were reported during the observation period. The few, minor changes in pituitary hormone concentrations were all within the reference range. They may be related to ranitidine treatment, but are more likely to be due to age-dependent alterations in hormone secretion. It is concluded that long-term treatment with ranitidine does not cause major changes in circulating hormone concentrations.
研究了组胺H2受体拮抗剂雷尼替丁(100或200毫克,每日两次,共6周,随后每日100或200毫克)对10名十二指肠溃疡男性患者垂体和外周激素血浆浓度的两年治疗效果。在治疗前、治疗期间(6个月和24个月)以及治疗后至少6个月进行了静脉注射200微克促甲状腺激素释放激素(TRH)和静脉注射100微克促黄体生成素释放激素(LHRH)的刺激试验。治疗6个月后基础和TRH刺激的催乳素(PRL)分泌略有减少,但24个月后未减少。治疗6个月、24个月以及治疗结束后,LH对LHRH的反应略有增加。治疗期间促甲状腺激素(TSH)、促卵泡激素(FSH)、皮质醇、雄激素和甲状腺激素的血浆浓度没有显著变化。观察期内未报告不良反应。垂体激素浓度的少数微小变化均在参考范围内。它们可能与雷尼替丁治疗有关,但更可能是由于激素分泌的年龄依赖性变化。结论是,雷尼替丁长期治疗不会引起循环激素浓度的重大变化。